Read more
This volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy.The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.
List of contents
Introduction.- Basic rules of T cell migration.- Regulation of anti-tumor T cell migration and function: contribution of real-time imaging.- Vascular normalization, T cell trafficking and anti-tumor immunity.- Disruption of anti-tumor T cell responses by cancer-associated fibroblasts.- Cancer-associated Tertiary Lymphoid Structures, from basic knowledge toward therapeutic target in clinic.- Homing Improvement: Boosting T Cell Trafficking for Cancer Immunotherapy.- Chemokines and T cell trafficking into tumors. Strategies to enhance recruitment of T cells into tumors.- Strategies to enhance migration and persistence of chimeric antigen receptor (CAR)-T cells into tumors.
About the author
Emmanuel Donnadieu, Ph.D, is a researcher and team leader of the 'Dynamics of T cell Interactions' group at the Cochin Institute. His recent research include breakthroughs in newly developed methods for following the migration and activation patterns of lymphocytes and other immune cells within tumors.
Summary
This volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy.The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.
